Time Between Treatment And PSA Recurrence Predicts Death From Prostate Cancer
According to a study last year at Fox Chase Cancer Center, men whose prostate specific antigen (PSA) rise within 18 months of having primary radiotherapy are more likely to develop advanced prostate cancer and die [...]
Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men with Biochemical Recurrence of Prostate Cancer
It has been clearly shown that androgen deprivation therapy (ADT) for the treatment of prostate cancer leads to loss of bone mineral density (BMD) and increased fracture risk. More importantly, loss of BMD shortens survival [...]
Carboplatin plus Paclitaxel Chemo After Failed Docetaxel – An Alternative When There Is None
Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens? [...]
Low-Dose Chemotherapy – Can It Work For Men Who Are Unable To Tolerate Normal Doses?
A study conducted at The Department of Urology, Yokosuka Kyosai Hospital, Japan, evaluated the efficacy and safety of using a low-dose chemotherapy combination of docetaxel, estramustine and dexamethasone in men with castrate resistant prostate cancer [...]
On the Horizon- Modified Citrus Pectin to fight Prostate Cancer
At Columbia University, New York City, Dr. Aaron Katz, in an online publication of Integrative Cancer Therapies reported positive effects on both androgen dependent (AD) and androgen independent (AI) prostate cancer of Modified Citrus Pectin [...]
Prostate Cancer Test Improves Prediction Of Disease Course- So Why Isn’t It Used?
In June of 2009 a team at UCSF Department of Urology announced a new prostate cancer risk assessment test that they claim can provide men and their doctors a better way of gauging long-term risks [...]